TIDMSLN

RNS Number : 8956J

Silence Therapeutics PLC

10 December 2018

Silence Therapeutics, PLC enters into a Settlement and License Agreement with Alnylam Pharmaceuticals

All legal proceedings, in all jurisdictions, between Silence and Alnylam are withdrawn with immediate effect

December 10, 2018

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today a Settlement and License Agreement with Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). Alnylam will license patents from Silence and will pay Silence a tiered royalty on net sales of ONPATTRO(TM) in the EU only ranging from 0.33 percent to 1.0 percent through 2023. All legal proceedings in all jurisdictions between the companies are resolved under the settlement.

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"We are excited for the potential of ONPATTRO(TM) to treat patients with hereditary ATTR amyloidosis polyneuropathy as the first RNAi medicine and are looking forward to following Alnylam's achievements. At Silence Therapeutics we now look forward to focusing on advancing a pipeline of competitive and differentiated medicines that will benefit patients and caregivers."

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU No. 596/2014). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Enquiries:

 
 Silence Therapeutics plc                       Tel: +44 (0)20 3457 
  Dr David Horn Solomon, Chief Executive         6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser and Broker)   Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                     8900 
 European IR                                    Tel: +44 (0) 20 
  Consilium Strategic Communications             3709 5700 
  Mary-Jane Elliott / Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                           Tel: +1 (443) 213-0505 
  Westwicke Partners 
  Peter Vozzo 
  peter.vozzo@westwicke.com

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRXKLLBVLFFFBX

(END) Dow Jones Newswires

December 10, 2018 02:00 ET (07:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Silence Therapeutics Charts.